A phase II trial reported the efficiency of lapatinib and capecitabine therapy against RM HNSCC [64], and our results showed an association between SPRR1A and CSTA expression with lapatinib response. The gene discussed is SPRR1A; the disease is head and neck squamous cell carcinoma.